Dogwood Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Dogwood Therapeutics, Inc. (DWTX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $33.52 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- Dogwood Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $16.69K.
- Dogwood Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $16.84K.
- Dogwood Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $16.56K.
- Dogwood Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $66.11K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $33.52K 10-Q · filed 2026-08-14 | $50.09K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2026-03-31 | $16.84K 10-Q · filed 2026-05-15 | $33.40K derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2025-12-31 | $16.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $66.11K 10-K · filed 2026-03-18 | ||
| 2025-09-30 | $49.55K 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |